European Stocks Flat as Oil Prices Rise, US CPI in Focus 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
France Keeps Top Health Alert as Officials Brace for Another Heatwave 
Asian Stocks Rise as Weak US Jobs Data Eases Fed Rate Hike Fears 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
Oil Prices Rise as US-Iran Talks Stall, Inflation Risks Grow 
Japan Posts First Current Account Deficit in 17 Months as Dividend Payments Surge 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Wall Street Slips as Oil Prices Surge 5% on Iran-Hormuz Uncertainty 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Asian Currencies Steady as Markets Await U.S. Inflation Data 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Oil Prices Rise as Hormuz Reopening Remains Uncertain 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Pfizer Inc.’s planned delivery of critical new medicines, such as respiratory syncytial virus (RSV) vaccine, to low-income nations, is likely to be delayed by several years due to several issues.
According to global health officials, Pfizer has not yet taken some of the necessary actions to make the vaccine accessible in developing nations.
They include getting the shot approved by the WHO and by nonprofit organizations that finance purchases in low-income countries, such as the global vaccine alliance Gavi.
Furthermore, the health agency prefers syringes that are automatically disabled after one injection for safety reasons to prevent reuse, but Pfizer's RSV vaccine is not made for those syringes.
Additionally, the RSV shot is only presently offered in single-dose vials. Multi-dose vials are frequently utilized in situations with less resources since they are less expensive and easier to distribute.
Preservatives must be added to multi-dose vials, therefore the manufacturer must do further tests to make sure there will be no impact on the vaccine's safety or effectiveness.
The vaccine will need a different delivery system to be used in developing countries in Africa and Asia, including alternative packaging and syringes.
Preparations for those modifications are just beginning, according to the World Health Organization.
Pfizer committed to more equitable access last year, following criticism that it prioritized wealthy nations for doses of its COVID-19 shot early in the pandemic. The company says it wants to shorten a timeline in which poorer countries often get vaccines many years after they are available elsewhere.
The drugmaker received a $28 million grant from the Bill and Melinda Gates Foundation in September to support the launch of the RSV vaccine in poorer countries, where RSV, a common cold-like virus, is much more likely to be lethal for very young children.
Pfizer's maternal RSV vaccine is expected to be approved for use in pregnant women in August in the US and several months later in Europe. Its peak sales forecast is more than $2 billion annually, together with the maternal vaccine and an RSV shot for older adults.
